The Covid pandemic drives Pfizer's 2022 revenue to a record $100 billion
Pfizer anticipates billions less in revenue this year as vaccines commercialized
Pfizer executives said the company expects a significant drop in revenue in 2023 compared to 2022 as the U.S. government ends its purchase agreement for COVID-19 vaccines and treatments. During its 2022 fourth-quarter earnings call Tuesday, CEO Albert Bourla said he anticipates 2023 to be a “transition year” as advance government purchases end and the…
Pfizer Rakes in Billions on COVID-19 Vaccine Sales, Highest Revenue in Company’s History
Vaccine maker Pfizer has reported record revenues for 2022, with its COVID-19 products accounting for a large chunk of the sales even as the company is facing backlash for claiming to “mutate” viruses, and a growing number of doctors are turning away from boosters.
Moderna’s stock is down as Pfizer lowers revenue estimates for its COVID vaccine for 2023
Moderna Inc.’s shares were down 2.8% in trading on Tuesday. Pfizer Inc. which makes a competing COVID-19 vaccine to Moderna’s Spikevax, on Tuesday put out...